Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*

Song, R; Zeng, G; Yu, JX; Meng, X; Chen, XY; Li, J; Xie, XL; Lian, XJ; Zhang, ZY; Cao, YL; Yin, WD; Jin, RH

Cao, YL (通讯作者)，Peking Univ, Biomed Pioneering Innovat Ctr, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.;Yin, WD (通讯作者)，Sinovac Biotech Ltd, 39, Shangdi West Rd, Beijing 100085, Peoples R China.;Jin, RH (通讯作者)，Capital Med Univ, Beijing Ditan Hosp, 8, Jingshun East St, Beijing 100015, Peoples R China.

EMERGING MICROBES & INFECTIONS, 2023; 12 (1):

Abstract

Monoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against coronavirus d......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索